Peptide Comparison
Melanotan II vs Melanotan I
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Melanotan II combined with novel peptides during dose-finding: High risk per peptide research literature. Masks individual peptide response (pigmentation, nausea, BP overlap); MC1R activation raises melanoma/mole darkening concerns when dose-finding other compounds.
Two MC1R agonists in the same regimen: Moderate-High risk per peptide research literature. Overlapping MC1R activation compounds melanogenesis, mole darkening, and the documented atypical-nevus / melanoma signal seen with chronic melanocortin exposure; the safety signal scales with cumulative MC1R activation.
Safety flag
They share a name but are different drugs with different safety profiles. Melanotan I (afamelanotide) is a selective MC1R agonist, FDA/EMA-approved for erythropoietic protoporphyria, delivered as a controlled SC implant under medical supervision. Melanotan II is a non-selective melanocortin agonist sold as a research chemical with documented case reports of mole darkening, melanoma changes, rhabdomyolysis, priapism, and BP effects. Pick Melanotan I if you have an EPP diagnosis and a prescription. Don't use Melanotan II.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
The actual difference
Melanotan I is selective for MC1R, the melanocyte receptor and the target you actually want for skin pigmentation. Melanotan II is non-selective and additionally activates MC3R/MC4R/MC5R, which is why it produces sexual arousal, appetite suppression, BP effects, and the off-target adverse-event profile that has accumulated in the case-report literature.
Which one to pick
Pick Melanotan II if
- Erythropoietic protoporphyria (the FDA/EMA-approved indication)
- Medically supervised photoprotection
- You can access the prescription pathway (Scenesse implant)
Pick Melanotan I if
- There is no defensible 'pick this' answer. Melanotan II is flagged 'Anecdotal (Editor-Flagged Unsafe)' in our catalog.
Avoid both if
- Personal history of melanoma or atypical nevi
- Photodermatosis without an EPP diagnosis (Melanotan I is approved for EPP specifically, not general tanning)
- Cardiovascular instability (especially relevant to MT-II's MC4R/MC5R activity)
Shared safety considerations
Both compounds share these reported concerns: nausea. Open each peptide page for the full risk paragraph and source citations.
Common confusions
- 'Melanotan I and II are basically the same drug, II is just the newer version'. False. They're different molecules with different receptor selectivity. MT-I is the medical-grade selective agonist; MT-II is the research-grade non-selective compound.
- 'Melanotan II is FDA-approved'. False. Only afamelanotide (MT-I) has FDA approval, and it's specifically for EPP, not for general tanning.
- 'Compounded MT-II from a US pharmacy is legal'. False in nearly all cases. Off-label compounding of unapproved peptides is restricted, and MT-II in particular is on most regulator 'do not use' lists.
Side-by-side
| Melanotan II | Melanotan I | |
|---|---|---|
| Class | Melanocortin receptor agonist (nonselective) | MC1R agonist; EU/FDA-approved for EPP |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Nonselective agonist at MC1R/MC3R/MC4R/MC5R; stimulates melanogenesis and sexual arousal pathways | Selective MC1R agonist; stimulates eumelanin production without sexual effects of MT-II |
| Route | SC injection | SC implant |
| Half-life | ~1-3 hrs | Implant (sustained release) |
| Dosage (research) | 0.25-1 mg SC daily titrating up | 16 mg SC implant every 2 months |
| Evidence tier | Anecdotal (Editor-Flagged Unsafe) | FDA/EMA-Approved |
| Research depth | 197 indexed | 150 indexed |
| Availability | Research Chemical | Prescription (EPP) |
| Reported risks | Nausea; facial flushing; melanoma/mole darkening concerns; priapism; BP effects; rhabdomyolysis reports | Injection site reactions; fatigue; nausea; melanin darkening |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Melanotan II or Melanotan I?
They share a name but are different drugs with different safety profiles. Melanotan I (afamelanotide) is a selective MC1R agonist, FDA/EMA-approved for erythropoietic protoporphyria, delivered as a controlled SC implant under medical supervision. Melanotan II is a non-selective melanocortin agonist sold as a research chemical with documented case reports of mole darkening, melanoma changes, rhabdomyolysis, priapism, and BP effects. Pick Melanotan I if you have an EPP diagnosis and a prescription. Don't use Melanotan II.
What is the difference between Melanotan II and Melanotan I?
Melanotan II is classed as Melanocortin receptor agonist (nonselective); Melanotan I is classed as MC1R agonist; EU/FDA-approved for EPP. Reported mechanism: Melanotan II, Nonselective agonist at MC1R/MC3R/MC4R/MC5R; stimulates melanogenesis and sexual arousal pathways; Melanotan I, Selective MC1R agonist; stimulates eumelanin production without sexual effects of MT-II. Reported half-life: Melanotan II, ~1-3 hrs; Melanotan I, Implant (sustained release). Routes in published studies: Melanotan II, SC injection; Melanotan I, SC implant.
Which has stronger evidence, Melanotan II or Melanotan I?
Melanotan I has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Melanotan II is graded Anecdotal (Editor-Flagged Unsafe), with 3 cited sources on its reference page and 197 indexed studies. Melanotan I is graded FDA/EMA-Approved, with 2 cited sources on its reference page and 150 indexed studies.
Which is more accessible, Melanotan II or Melanotan I?
Melanotan I is FDA-approved and Melanotan II is not. Catalog status: Melanotan II, Research Chemical; Melanotan I, Prescription (EPP). Melanotan II's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are Melanotan II and Melanotan I ever combined?
Melanotan II and Melanotan I appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two MC1R agonists in the same regimen, moderate-high risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…